CN111317857A - Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof - Google Patents
Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof Download PDFInfo
- Publication number
- CN111317857A CN111317857A CN201811540249.6A CN201811540249A CN111317857A CN 111317857 A CN111317857 A CN 111317857A CN 201811540249 A CN201811540249 A CN 201811540249A CN 111317857 A CN111317857 A CN 111317857A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- hemostatic material
- molecular weight
- stirring
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0042—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Abstract
The invention discloses a degradable and absorbable bone hemostatic material containing chitosan and a preparation method thereof. The bone hemostatic material comprises: two polyethylene glycols and chitosan of different molecular weights; wherein the mass fraction of the chitosan is 1-30%. The preparation method comprises the following steps: stirring and mixing two polyethylene glycols with different molecular weights, and heating to enable the mixture to be in a clear liquid state; slowly adding the chitosan with the dosage, stirring and mixing uniformly, curing and sterilizing to obtain the bone hemostatic material. The bone hemostatic material is white wax, has good kneading plasticity, can perform hemostasis on bone wounds in a physical blocking mode, and contains the chitosan component with good hemostatic and healing promoting performances. Meanwhile, the material can be degraded and absorbed in human body, and has no toxic or harmful effect on human body.
Description
Technical Field
The invention relates to the technical field of biomedical materials, in particular to a degradable and absorbable bone hemostatic material containing chitosan and a preparation method thereof.
Background
The bone surgery wound is often larger, no exact hemostasis means exists at present for cancellous bone surface bleeding, venous sinus bleeding, bleeding of a bone marrow cavity and the like in the operation, a large amount of blood loss is common in the operation, blood transfusion is often needed in time to supplement blood volume, and the risk of suffering from blood infectious diseases is increased. Therefore, in the surgical repair of Bone, it is important to take appropriate hemostatic measures, and the most commonly used Bone hemostatic material in clinical practice today is Bone Wax (Bone Wax).
The existing commonly used bone wax hemostatic material is usually prepared by mixing beeswax, paraffin, vaseline and other raw materials according to a certain mass ratio, and the product is white or light yellow and has good softening performance, can be shaped after being kneaded and softened by hands and is nontoxic. The hemostatic effect is achieved by blocking capillary vessels seeping from bones through a pure physical method, and the product has no functions of stopping bleeding and promoting bone healing. Although the traditional bone wax is widely applied to bone hemostasis, the preparation cost is low, and the process is relatively simple, due to the characteristic of non-degradability and non-absorbability, the traditional bone wax can be always present in a human body as a variant to inhibit the bone healing process, and meanwhile, chronic inflammation and obvious foreign body reaction can be caused, the bacterial clearance is reduced, the bone infection risk is increased, and the like.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides a degradable and absorbable bone hemostatic material containing chitosan and a preparation method thereof. To replace traditional bone wax.
The invention aims to provide a degradable and absorbable bone hemostatic material containing chitosan.
The method comprises the following steps:
two polyethylene glycols and chitosan of different molecular weights;
wherein the mass fraction of the chitosan is 1-30%; preferably 10 to 20 percent;
among them, preferred are:
the chitosan has deacetylation degree of 50-95% and molecular weight of 5000-100000.
The molecular weight of the polyethylene glycol is 200 to 20000.
The two polyethylene glycols with different molecular weights are low molecular weight polyethylene glycol and high molecular weight polyethylene glycol;
in the two polyethylene glycols with different molecular weights, the mass percentage of the low molecular weight polyethylene glycol is 10-50%, and the mass percentage of the high molecular weight polyethylene glycol is 50-90%.
The molecular weight of the low molecular weight polyethylene glycol is 200-600;
the molecular weight of the high molecular weight polyethylene glycol is 800-20000;
polyethylene glycol (PEG) is a non-toxic, non-irritating, well water-soluble polymer, varying in nature depending on the relative molecular mass, from a colorless, odorless, viscous liquid to a waxy solid. Polyethylene glycols and polyethylene glycol fatty acid esters are widely used in the cosmetic and pharmaceutical industries. Polyethylene glycol has many excellent properties: water-soluble, non-volatile, physiologically inert, mild, lubricious, and moisturized, soft, pleasant after-feel, etc. The polyethylene glycol can be selected in different relative molecular mass fractions to alter the viscosity, hygroscopicity and texture of the product. Polyethylene glycol is widely used in various pharmaceutical preparations such as injections, topical preparations, ophthalmic preparations, oral and rectal preparations. Oxidized cellulose has certain hemostatic function and is commonly used for moderate bleeding which can not be sutured or ligated in surgical operation.
The second purpose of the invention is to provide a preparation method of a degradable and absorbable bone hemostatic material containing chitosan.
The method comprises the following steps:
stirring and mixing two polyethylene glycols with different molecular weights, and heating to enable the mixture to be in a clear liquid state; slowly adding the chitosan with the dosage, stirring and mixing uniformly, curing and sterilizing to obtain the bone hemostatic material.
Among them, preferred are:
the heating temperature is 50-60 ℃, and the stirring time is 1-3 hours
The invention can adopt the following technical scheme:
a bone hemostatic material that is completely degradable and absorbable and has excellent hemostatic properties, the material comprising:
(1) two polyethylene glycols (PEGs) of different molecular weights in a mass ratio of 10/90;
(2) 1-30% of chitosan by mass.
Preferably, the polyethylene glycol has a molecular weight of 200 to 20000.
Preferably, the chitosan has a deacetylation degree of 50-95% and a molecular weight of 5000-100000.
A preparation method of a bone hemostatic material which is completely degradable and absorbable and has excellent hemostatic performance comprises the following steps:
(1) heating two polyethylene glycols with different molecular weights to 50-60 ℃ under the condition of mechanical stirring, and stirring for 10 minutes to enable the mixture to be in a clear liquid state;
(2) slowly adding chitosan into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing at the heating temperature of 50-60 ℃ for 1-3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured product, sealing, and sterilizing under high pressure or gamma ray
The bone hemostatic material is white wax, has good kneading plasticity, can perform hemostasis on bone wounds in a physical blocking mode, and contains the chitosan component with good hemostatic and healing promoting performances. Meanwhile, the material can be degraded and absorbed in human body, and has no toxic or harmful effect on human body.
Drawings
FIG. 1 is a graph of the melting temperatures of different molecular weight polyethylene glycols;
FIG. 2 is a graph of crystallization temperatures for different molecular weight polyethylene glycols;
fig. 3 is a cytotoxicity diagram of the bone hemostatic material provided in embodiment 6 of the present invention. As shown in the figure, the number of cells shows a steady growth trend along with the increase of time, which shows that the material has good biocompatibility and no cytotoxicity.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1
(1) Heating 2g of polyethylene glycol 200 (aldin company) and 18g of polyethylene glycol 10000 (aldin company) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to enable the mixture to be in a clear liquid state;
(2) slowly adding 5% chitosan with deacetylation degree of 95% and molecular weight of 5000 into the uniformly mixed liquid under heating condition of keeping mechanical stirring, and stirring and mixing uniformly at heating temperature of 60 deg.C for 3 hr;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 2
(1) Heating 4g of polyethylene glycol 400 (aldin) and 16g of polyethylene glycol 1500 (aldin) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding chitosan with the mass fraction of 1% and the deacetylation degree of 80% and the molecular weight of 50000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing at the heating temperature of 60 ℃ for 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 3
(1) Heating 10g polyethylene glycol 200 (aldin company) and 10g polyethylene glycol 8000 (aldin company) under mechanical stirring at 60 deg.C, and stirring for 10 min to obtain clear liquid;
(2) slowly adding chitosan with the mass fraction of 10% and the deacetylation degree of 80% and the molecular weight of 10000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing, wherein the heating temperature is 60 ℃, and the stirring time is 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 4
(1) Heating 8g polyethylene glycol 400 (aldin company) and 12g polyethylene glycol 8000 (aldin company) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to make the mixture to be in a clear liquid state;
(2) slowly adding 5% chitosan with deacetylation degree of 95% and molecular weight of 50000 into the uniformly mixed liquid under heating condition of keeping mechanical stirring, and stirring and mixing uniformly at heating temperature of 60 deg.C for 3 hr;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 5
(1) Heating 4g of polyethylene glycol 200 (aldin) and 16g of polyethylene glycol 1500 (aldin) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding chitosan with the mass fraction of 15 percent and the deacetylation degree of 95 percent and the molecular weight of 100000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing, wherein the heating temperature is 60 ℃, and the stirring time is 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 6
(1) Heating 2g of polyethylene glycol 400 (aldin) and 18g of polyethylene glycol 1500 (aldin) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding chitosan with the mass fraction of 20 percent and the deacetylation degree of 95 percent and the molecular weight of 100000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing, wherein the heating temperature is 60 ℃, and the stirring time is 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and molded product, sealing, and sterilizing by high pressure or gamma ray;
(5) the bone hemostatic material prepared by the method is co-cultured with preosteoblasts MC3T 3-E1. The absorbance of the cell sap at 450nm was measured at different time points. As shown in FIG. 3, the number of cells increases with time, which indicates that the absorbable bone hemostatic material prepared by the invention has good biocompatibility and no cytotoxicity.
Example 7
(1) Heating 2g of polyethylene glycol 600 (aldin) and 18g of polyethylene glycol 800 (aldin) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding 30% chitosan with deacetylation degree of 95% and molecular weight of 10000% into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and stirring and mixing uniformly at the heating temperature of 60 ℃ for 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 8
(1) Heating 8g of polyethylene glycol 600 and 12g of polyethylene glycol 20000 (alddin company) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding chitosan with the mass fraction of 80% and the molecular weight of 50000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing at the heating temperature of 60 ℃ for 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 9
(1) Heating 10g polyethylene glycol 600 (aldin) and 10g polyethylene glycol 800 (aldin) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to make the mixture to be in a clear liquid state;
(2) slowly adding chitosan with the mass fraction of 15 percent and the molecular weight of 100000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing, wherein the heating temperature is 60 ℃, and the stirring time is 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 10
(1) Heating 2g polyethylene glycol 400 (aldin) and 18g polyethylene glycol 4000 (aldin) to 55 ℃ under mechanical stirring, and stirring for 10 minutes to make the mixture to be in a clear liquid state;
(2) slowly adding 10% by mass of chitosan with the deacetylation degree of 90% and the molecular weight of 20000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing at the heating temperature of 55 ℃ for 2 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 11
(1) Heating 2g of polyethylene glycol 200 (aldin) and 18g of polyethylene glycol 3000 (aldin) to 60 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding 5% by mass of chitosan with the deacetylation degree of 50% and the molecular weight of 5000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing at the heating temperature of 60 ℃ for 1 hour;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Example 12
(1) Heating 2g polyethylene glycol 400 (aldin) and 18g polyethylene glycol 3000 (aldin) to 50 ℃ under mechanical stirring, and stirring for 10 minutes to obtain a clear liquid;
(2) slowly adding chitosan with the mass fraction of 5 percent and the deacetylation degree of 95 percent and the molecular weight of 100000 into the uniformly mixed liquid under the heating condition of keeping mechanical stirring, and uniformly stirring and mixing, wherein the heating temperature is 50 ℃, and the stirring time is 3 hours;
(3) pouring the uniformly mixed mixture into a prepared mould or a split charging bottle, and standing for 2 hours at normal temperature for curing and forming;
(4) packaging the cured and formed product, sealing, and sterilizing by high pressure or gamma ray.
Claims (8)
1. A degradable and absorbable bone hemostatic material containing chitosan, which is characterized by comprising:
two polyethylene glycols and chitosan of different molecular weights;
wherein the mass fraction of the chitosan is 1-30%.
2. The chitosan-containing degradable and absorbable bone hemostatic material of claim 1, wherein:
the mass fraction of the chitosan is 10-20%.
3. The chitosan-containing degradable and absorbable bone hemostatic material of claim 1, wherein:
the chitosan has deacetylation degree of 50-95% and molecular weight of 5000-100000.
4. The chitosan-containing degradable and absorbable bone hemostatic material of claim 1, wherein:
the molecular weight of the polyethylene glycol is 200 to 20000.
5. The chitosan-containing degradable and absorbable bone hemostatic material of claim 4, wherein:
the two polyethylene glycols with different molecular weights are low molecular weight polyethylene glycol and high molecular weight polyethylene glycol;
in the two polyethylene glycols with different molecular weights, the mass percentage of the low molecular weight polyethylene glycol is 10-50%, and the mass percentage of the high molecular weight polyethylene glycol is 50-90%.
6. The chitosan-containing degradable and absorbable bone hemostatic material of claim 5, wherein:
the molecular weight of the low molecular weight polyethylene glycol is 200-600;
the molecular weight of the high molecular weight polyethylene glycol is 800-20000.
7. A method for preparing a chitosan-containing degradable and absorbable bone hemostatic material as set forth in any one of claims 1 to 6, wherein the method comprises:
stirring and mixing two polyethylene glycols with different molecular weights, and heating to enable the mixture to be in a clear liquid state; slowly adding the chitosan with the dosage, stirring and mixing uniformly, curing and sterilizing to obtain the bone hemostatic material.
8. The method of claim 7, wherein:
the heating temperature is 50-60 ℃, and the stirring time is 1-3 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811540249.6A CN111317857A (en) | 2018-12-17 | 2018-12-17 | Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811540249.6A CN111317857A (en) | 2018-12-17 | 2018-12-17 | Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111317857A true CN111317857A (en) | 2020-06-23 |
Family
ID=71168947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811540249.6A Pending CN111317857A (en) | 2018-12-17 | 2018-12-17 | Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111317857A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113521376A (en) * | 2021-07-22 | 2021-10-22 | 赛克赛斯生物科技股份有限公司 | Surgical sealant kit and application thereof in brain and spinal surgery |
| CN114288462A (en) * | 2021-12-03 | 2022-04-08 | 北京大学口腔医院 | Hemostatic material |
| CN114404642A (en) * | 2022-04-01 | 2022-04-29 | 天新福（北京）医疗器材股份有限公司 | Absorbable hemostatic bone paste and preparation method thereof |
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816905A (en) * | 2016-04-15 | 2016-08-03 | 广州贝奥吉因生物科技有限公司 | Absorbable bone wax with heal-promoting function and preparation method of absorbable bone wax |
| CN107158452A (en) * | 2017-05-05 | 2017-09-15 | 山东赛克赛斯生物科技有限公司 | A kind of bone surface of a wound hemostatic composition and its preparation method and application |
-
2018
- 2018-12-17 CN CN201811540249.6A patent/CN111317857A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105816905A (en) * | 2016-04-15 | 2016-08-03 | 广州贝奥吉因生物科技有限公司 | Absorbable bone wax with heal-promoting function and preparation method of absorbable bone wax |
| CN107158452A (en) * | 2017-05-05 | 2017-09-15 | 山东赛克赛斯生物科技有限公司 | A kind of bone surface of a wound hemostatic composition and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| DENNIS P. ORGILL等: "Polyethylene glycol/microfibrillar collagen composite as a new resorbable hemostatic bone wax", 《J BIOMED MATER RES》 * |
| THERESA BRUCKNER等: "Novel bone wax based on poly(ethylene glycol)-calcium phosphate cement mixtures", 《ACTA BIOMATERIALIA》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
| CN113521376A (en) * | 2021-07-22 | 2021-10-22 | 赛克赛斯生物科技股份有限公司 | Surgical sealant kit and application thereof in brain and spinal surgery |
| CN114288462A (en) * | 2021-12-03 | 2022-04-08 | 北京大学口腔医院 | Hemostatic material |
| CN114404642A (en) * | 2022-04-01 | 2022-04-29 | 天新福（北京）医疗器材股份有限公司 | Absorbable hemostatic bone paste and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111317857A (en) | Degradable and absorbable bone hemostatic material containing chitosan and preparation method thereof | |
| US4443430A (en) | Synthetic absorbable hemostatic agent | |
| JP5763665B2 (en) | Embedding paste and its use | |
| EP2626092B1 (en) | Medical absorbable hemostatic material for bone wounds and preparation method therefor | |
| KR20010104341A (en) | Suture material for wounds based on methylidene malonate | |
| WO2000062827A3 (en) | Rapid gelling biocompatible polymer composition | |
| JP6095675B2 (en) | Non-aqueous compositions for bone hemostasis and methods for using and manufacturing them | |
| JP2014530066A5 (en) | ||
| US10022411B2 (en) | Hemostatic preparation containing an extract of golden moss | |
| KR20130101974A (en) | Biomaterial | |
| KR101989054B1 (en) | Hemostatic agent and container containing the same | |
| WO1992013578A1 (en) | A biologically derived medical adhesive and its uses | |
| CN111317858A (en) | Degradable and absorbable bone hemostatic material and preparation method thereof | |
| KR20160075535A (en) | Method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine added in powder form, and an alkaline agent, sterilized with heat | |
| CN114369441A (en) | Polyphenol-based medical tissue adhesive, and preparation method and application thereof | |
| CN115400260B (en) | Repairing gel containing recombinant humanized collagen and preparation method thereof | |
| AU2017310470B2 (en) | Hemostatic flowable | |
| KR101980063B1 (en) | Sponge Type Biodegradable Hemostatic Compositions Containing Hyaluronic Acid | |
| WO1986001113A1 (en) | Bone-replacing material | |
| WO2019231763A1 (en) | Tissue adhesives and sealants using naturally derived aldehydes | |
| EP0572272B1 (en) | Absorbable bone sealant | |
| AU652808B2 (en) | A biologically derived medical adhesive and its uses | |
| CN114470307B (en) | Degradable hemostatic plugging adhesive and preparation method thereof | |
| CN115887741B (en) | Absorbable bone wax and preparation method thereof | |
| CN117653774A (en) | Healing powder composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200623 |